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Abstract
Background: Transfusion associated Hepatitis B virus (TAHBV) continues to be a major problem despite mandatory
screening for Hepatitis B surface Antigen (HBsAg). Presence of HBsAg is the common method for detecting
hepatitis B infection. Unfortunately, this marker is not detected during the window period of the infection. Nigeria
being a developing country cannot afford DNA testing of all collected units of blood which serve as the only
possibility of achieving zero risk of transfusion associated HBV. Five different serological makers of hepatitis B virus
(HBV) infection were therefore assessed to evaluate the reliability of using HBsAg marker alone in diagnosis of HBV
infection among blood donors and to detect the serological evidence of the infection at the window period. This
will preclude the possibility of transmitting hepatitis B through transfusion of Hepatitis B surface antigen (HBsAg)
negative blood in Nigeria.
Methods: Between July and August 2009, 92 blood donors were enrolled for the study. The prevalence of 5
different markers of Hepatitis B virus infection was detected using Enzyme Linked Immunosorbent Assay (ELISA).
Demographic factors were assessed during the study.
Results: HBsAg and its antibody (anti-HBs) was detected in 18 (19.6%) and 14(15.2%) of the 92 blood donors
respectively. Anti-HBc IgM was found in 12(13.0%) of the 92 blood donors while Hepatitis B envelope antigen
(HBeAg) and its antibody (anti-HBe) were detected in 4(8.9%) and 12(26.7%) respectively from 45 donors sampled.
HBeAg is a marker of high infectivity and appears after HBsAg. At least one serological marker was detected in 30
(32.6%) of the blood donors. Five (5.4%) of the 92 donors had anti-HBc IgM as the only serological evidence of
hepatitis B virus infection.
Conclusions: The result of this study shows that five donors have anti-HBcIgM as the only serological evidence of
HBV infection. Inclusion of anti-HBcIgM in routine screening of blood donors in Nigeria should be encouraged. This
is the first study to assess anti-HBcIgM in the country.
Keywords: Hepatitis B, Transfusion, Serological markers, ELISA, Blood donors
Background
Hepatitis B virus (HBV) infection with its associated
sequel is a disease of major public health importance,
being the 10
th leading cause of death globally [1,2]. HBV
infection accounts for 500,000 to 1.2 million deaths
each year [3]. Of the approximately 2 billion people
infected worldwide, more than 350 million are chronic
carriers of HBV [4]. Approximately 15-40% of infected
patients will develop cirrhosis, liver failure or hepatocel-
lular carcinoma (HCC) [5,6]
The aetiological agent (Hepatitis B virus) is a member
of the family Hepadnaviridae and the genus Orthohepad-
navirus [7]. It is a double stranded circular DNA virus
composed of an outer envelope containing hepatitis B
surface antigen (HBsAg) and an inner nucleocapsid con-
sisting of hepatitis B envelope antigen (HBeAg) and
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dies to each of these antigens are Hepatitis B surface
antibody (anti-HBs or HBsAb), Hepatitis B envelope anti-
body (anti-HBe or HBeAb) and hepatitis B core IgM and
IgG antibody (anti-HBc or HBcAb) [8]. The viral core
also contains double stranded DNA genome and DNA
polymerase. The serological markers of Hepatitis B virus
are HBsAg, anti-HBs, HBcAg, anti-HBc (IgM and IgG),
HBeAg, anti-HBe, and HBV DNA; these are important as
they can be used in the diagnosis of the infection and to
determine the severity of the infection [9].
Following infection by the hepatitis B virus (HBV), the
first serological marker to appear in the blood is the HBV
DNA, followed by HBsAg, the DNA polymerase and
HBeAg. Thereafter, the antibodies to the hepatitis B anti-
gens (HBcAb, HBeAb and HBsAb) can be detected.
Screening of donated blood by enzyme-linked immuno-
sorbent assay (ELISA) for HBsAg is the common method
for detecting hepatitis B infection [10]. Screening of blood
for the detection of this viral marker, however, does not
rule out the risk of transmission of hepatitis B totally,
because during the host serological response to infection,
there is a phase during which the HBsAg cannot be
detected in the blood although hepatitis B infection is pre-
sent. This phase is known as the ‘window period’.I tr e p r e -
sents a carrier state of the disease.
Findings indicate that testing done for HBsAg alone is
not sufficient to eliminate HBV infection from blood sup-
ply [10-13]. A marker which would be indicative of hepati-
tis B infection during the window period is thus of
paramount importance in blood banking especially in low
income country like Nigeria, where DNA testing of all col-
lected units of blood is not feasible.
This study was therefore designed to evaluate the relia-
bility of using HBsAg marker alone, in diagnosis of HBV
infection among blood donors and to detect the presence
of a marker which would be indicative of hepatitis B infec-
tion during the window period.
Results and Discussion
Results
Prevalence of HBV Marker
Of the 92 blood samples tested, HBsAg was detected in 18
(19.6%), anti-HBs in 14(15.2%) and anti-HBcIgM in 12
(13.0%). HBeAg and anti-HBe were detected in 4(8.9%)
and 12(26.7%) respectively from 45 donors sampled. Table
1 summarises the frequency of the 5 markers of HBV
tested among the blood donors. At least one serological
marker was detected in 30(32.6%) of the blood donors
(Table 2). Five (5.4%) of the donors had anti-HBcIgM as
the only serological evidence of hepatitis B virus infection.
Sex and Age distribution of donors with HBV marker
Of the 69 male blood donors enrolled for this study,
15 (21.7%) 13(18.8%) and12 (17.4%) were positive for
HBsAg, HBsAb and Anti-HBcIgM respectively while 4
(8.9%) and 12 (26.7%) were positive for HBeAg and
HBeAb respectively among the 45 donors tested. Among
the 23 females enrolled in the study no positivity was
recorded for HBcAb, HBeAg and its Ab, however, 3(13%)
and 1(4.3%) were positive for HBsAg and Ab respectively.
(Table 3). There is no significant difference (P < 0.005)
between the sex distribution of HBV markers among
blood donors. The age distribution of blood donors with
serological marker is shown in table 4.
Discussion
Transfusion of blood collected from a donor who is in
the window period may lead to post transfusion hepati-
tis B in the recipient [14,15]. The result of this study
showed that 5 donors (5.4%) had anti-HBcIgM antibody
as the only serologic evidence of HBV. They have not
seroconverted to anti-HBs, hence might be infectious.
Previous studies have demonstrated the presence of
HBV DNA in anti-HBc-only donors [16,17]. These find-
ings corroborate earlier report that testing blood donors
for HBsAg alone is not sufficient to eliminate HBV from
blood supply [11]
Chaudhuri et al., 2003 observe the presence of HBV
DNA in one-fifth of anti-HBc-only donors studied and
stated that, reactivity to anti-HBc only can predict cryp-
tic HBV infection. A report from Japan [16] demon-
strated the presence of HBV DNA in 38 percent of
HBsAg-negative anti-HBc-reactive donors. The only ser-
ologic evidence of infection with hepatitis B in 5 of the
92 blood donors in this study is the presence of IgM
antibody to the core antigen (HBcIgM). Blood from the
5 anti-HBc IgM only donors from this study might have
been transfused to innocent patients (since the donors
were screened negative due to no detectable HBsAg in
their blood), thereby increasing the number of possible
post transfusion HBV.
It had been observed earlier [10,14,15] that the screen-
ing test for detection of HBsAg does not rule out the
transmissions of Hepatitis B as the donor might be in
the “window period” and detection of the antibody to
the hepatitis B core antigen HBcIgM type serves as a
useful serological marker during this period. A preva-
lence of 5.4% observed for anti-HBc in this study is
Table 1 Prevalence of Hepatitis B Virus Serological
markers among blood donors
SEROLOGICAL MARKERS NUMBER OF SAMPLES POSITIVE (%)
HBsAg 92 18(19.6)
HBsAb 92 14(15.2)
HBeAg 45 4(8.9)
HBeAb 45 12(26.7)
HBcIgM 92 12(13.0)
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This might be indicating a pro g r e s s i v ei n c r e a s ei nt h e
possibility of transfusing HBV through blood donation.
Anti-HBc has been found to be an excellent indicator
of occult HBV infection during the window period
[18,19,15]. Other markers for detecting occult HBV
i n f e c t i o ni na nH B s A gn e g a t i v eb l o o dd o n o rs u c ha s
detection of HBV DNA by polymerase chain rection
(PCR) may not be cost effective [20]). Detection of anti-
HBc has contributed significantly in reducing the
incidence of post transfusion hepatitis B amongst
patients [21-23]. The IgM class of the anti-HBc is a
marker that indicates recent infection. The IgG variety
of anti-HBc appears later during the infection and
points to a past HBV infection. Individuals with IgG
variety of anti-HBc may not be infectious as they may
have sufficiently high titres of antibodies to HBsAg
( a n t i - H B s ) ,w h i c ha r ep r o t e c t i v ei nn a t u r ea n dt h e
affected individuals may actually be disease free. The
sero-prevalence rate of anti-HBcIgM in the general
Table 2 Donors showing detectable evidence of HBV infection by presence of at least one serological marker
S/N Sample code Age Sex SEROLOGICAL MARKERS
HBsAg HBsAb HBcIgM HBeAg HBeAb
1 111 30 M ✓✓ ✓
2 117 23 M ✓✓
3 137 19 M ✓✓
4 138 41 M ✓✓
57 9 4 5 M ✓✓ ✓
68 0 3 7 M ✓✓ ✓
7 112 29 M ✓✓ ✓
8 113 22 M ✓✓
9 121 22 M ✓✓
10 124 35 M ✓✓
11 153 19 M ✓✓
12 154 21 M ✓✓ ✓
13 155 20 M ✓✓
14 157 28 M ✓✓ ✓
15 158 32 M ✓✓ ✓
16 116 23 M ✓✓ ✓
17 123 27 M ✓
18 163 33 M ✓✓
19 165 23 M ✓
20 189 22 M ✓
21 203 26 M ✓✓
22 15-5 29 M ✓
23 04 21 M ✓
24 07 27 F ✓
25 08 36 M ✓✓
26 210 23 M ✓✓
27 215 19 F ✓
28 69 20 F ✓✓
29 190 21 M ✓
30 124 28 M ✓✓
TOTAL 18 14 12 4 12
Table 3 Sex distribution of blood donors with HBV markers
Number Tested (%) Positive (%) Positive (%)
HBsAg HBsAb Anti-HBcIgM No tested for HBeAg &Ab HBeAg HBeAb
Male 69(75%) 15 (21.7) 13 (18.8) 12 (17.4) 45 4 (8.9) 12(26.7)
Female 23(25%) 3 (13.0) 1 (4.3) 0 (0) 45 0 (0) 0 (0)
Total 92 18 14 12 45 4 12
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knowledge, the only published data on estimation of
a n t i - H B ci nN i g e r i aw a so nt h ep r e v a l e n c eo fa n t i - H B c
total (i.e. both IgG and IgM) amongst patients with
chronic liver disease and it was estimated as 90% [24].
Anti-HBcIgG may remain positive for life in an infected
individual although the individual has protective levels
of anti-HBs and therefore does not necessarily mean
that blood of such a donor is infectious. Consequently,
anti-HBcIgM is considered to be a more specific marker
for HBV infection during the window period [25-27].
Conclusion
The result of this study shows the need to include anti-
HBcIgM in routine screening of blood donors in Nigeria.
It also confirms the fact that testing blood donors for
HBsAg alone is not sufficient to eliminate HBV from
blood supply. Although, the possibility of achieving zero
risk of transfusion associated HBV infection depend lar-
gely on DNA testing of all the collected units of blood [13]
before transfusion; however, since this is not done in many
developing countries including Nigeria due to cost, this
study recommends the inclusion of anti-HBcIgM in rou-
tine screening of blood donors in countries where DNA
testing is not done. This will go a long way in reducing
transfusion associated Hep a t i t i sBV i r u s( T A H B V )
infection.
Methods
Sample Collection and Preparation
Ninety-two (M = 69, F = 23; Age range: 18-50 years;
Mean: 24.9 years) blood donors in Ile-Ife, Osun State were
enrolled for the study between July and August 2009. Five
millilitres of blood was collected from each donor by vene-
puncture into a labelled sterile container free of anticoagu-
lants or preservative. Each blood specimen was separated
by low centrifugation at 500 g for 5 minutes and the
serum transferred into labelled cryovial. Thereafter, the
sera were kept frozen at -20C until analysed.
Assay procedure
Five different markers of HBV infection (HBsAg, anti-
HBs, anti-HBcIgM, HBeAg and anti-HBe) were detected
by commercial Enzyme-linked immunosorbent assay
(ELISA) kit (Diapro Diagnotic Bioprobes Milano- Italy).
The kit, reagent and sera were brought to room tempera-
ture before starting the assay. The wells of each of the
microplate were identified for controls and samples. For
each of the assays, there were two negative controls and
one positive control. One hundred microlitres each of
negative control, positive control and sample were
pipetted into the appropriate wells except for HBsAg
where 50 μl was used as stated by the manufacturer. The
plates were incubated at 37°C for 60 minutes, washed
with wash buffer 5 times with soaking time of about 30
seconds in between each washing. A second incubation
at same temperature and time was carried out after the
addition of enzyme conjugate and the plates were washed
as previously described. A final incubation at room tem-
perature for 10 to 15 minutes depending on manufac-
turer’s instruction for the specific serological marker was
done after the addition of substrate (a chromogen). This
made the positive samples turn to blue while the nega-
tives were colourless. Addition of 100 μl of the stop solu-
tion (sulphuric acid) turned the positive samples from
blue to yellow. The results were read using a 450 nm fil-
ter microplate reader.
Statistical analysis
The prevalence of serological markers was compared in
terms of gender by use of chi-square tests.
List of Abbrevations
Anti-HBcIgM: Hepatitis B Core IgM Antibody; HBsAg:
Hepatitis B surface Antigen; TAHBV: Transfusion Asso-
ciated Hepatitis B Virus; HBV: Hepatitis B Virus; ELISA:
Enzyme Linked Immunosorbent Assay; Anti-HBs or
HBsAb: Hepatitis B surface Antibody; HBeAg: Hepatitis
B envelope Antigen; Anti-HBe or HBeAb: Hepatitis B
envelope antibody.
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